Precision BioSciences, Inc. , a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today ...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new ...

On-demand video webcast now available here AURORA, CO / ACCESS Newswire / February 19, 2025 / Exxel Pharma("Exxel" or the ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Paysign's strategic focus on Plasma and Patient Affordability programs has driven significant growth. Read more to see why ...

Paul Owen has been appointed as Chief Executive Officer of YourBio Health, a pioneer in remote blood collection technology, and CEO-Partner of Flagship Pioneering, a bioplatform innovation company.

MSK plans to speed up early-stage drug development by using AWS Drug Discovery Workbench to screen potential candidates.

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placeboSPN-820 was well-tolerated ...

As Republicans gear up to pass the first major tax bill since the 2017 Tax Cuts and Jobs Act, Citibank hired Ernst & Young ...

Product sales for the vaccine specialist Valneva reached €170m despite slow US sales of its chikungunya vaccine.

Seqens, a developer and producer of active pharmaceutical ingredients, pharmaceutical intermediates, and specialty ingredients, has named Pascal Villemagne as Chief Executive Officer, effective April ...

Supernus Pharmaceuticals (NASDAQ:SUPN) stock drops as depression candidate SPN-820 misses main goals in Phase 2b trial. Read more here.